Thiazolidinedione Treatment Attenuates Diffuse Neointimal Hyperplasia in Restenotic Lesions After Coronary Stent Implantation in Type 2 Diabetic Patients: An Intravascular Ultrasound Study
|
Accession number;05A0361321
|
| Title;Thiazolidinedione Treatment Attenuates Diffuse Neointimal Hyperplasia in Restenotic Lesions After Coronary Stent Implantation in Type 2 Diabetic Patients: An Intravascular Ultrasound Study |
| Author;
TAKAGI TSUTOMU
(Takagi Cardiology Clinic, Kyoto)
YAMAMURO ATSUSHI
(Kobe General Hospital, Kobe)
TAMITA KOICHI
(Kobe General Hospital, Kobe)
KATAYAMA MINAKO
(Kobe General Hospital, Kobe)
MORIOKA SHIGEFUMI
(Kobe General Hospital, Kobe)
|
Journal Title;J Cardiol
|
Journal Code:Y0264A
|
ISSN:0914-5087
|
|
VOL.45;NO.4;PAGE.139-147(2005)
|
| Figure&Table&Reference;FIG.5, TBL.3, REF.43 |
| Pub. Country;Japan |
| Language;English |
| Abstract;Objectives. Thiazolidinedione treatment reduces neointimal tissue proliferation after coronary scent implantation in diabetic patients. However, in-stent restenosis still persists in patients treated with thiazolidinedione. The effect of thiazolidinedione treatment on the pattern of in-stent restenosis remains unclear. This study investigated whether thiazolidinedione treatment attenuates diffuse neointimal hyperplasia in restenotic lesions after coronary stent implantation in diabetic patients. Methods. Volumetric intravascular ultrasound was performed at 6 months after coronary stent implantation in 76 patients with restenotic lesions who received either conventional anti-diabetic treatment (control group, n=56) or thiazolidinedione treatment (thiazolidinedione group, n=20). Results. There were no significant differences between the two groups in stent volume (99.+-.32 vs 90.+-.20mm'3', respectively, p=0.26) or in minimal lumen area in the stent (1.4.+-.0.6 vs 1.6.+-.0.5mm'2', respectively, p=0.11). However, there were significant reductions in neointimal volume (56.+-.25 vs 36.+-.11mm'3', respectively, p<0.01) and neointimal index (56.+-.11% vs 41.+-.8%, respectively, p<0.01) in the thiazolidinedione group. Coefficient of variation of neointimal tissue accumulation was greater in the thiazolidinedione group (45.5%) than in the control group (25.2%). Conclusions. Intravascular ultrasound study demonstrated that together with reduction of overall neointimal tissue proliferation, thiazolidinedione treatment caused greater point-to-point heterogeneity in the neointimal tissue accumulation in restenotic lesions after coronary stent implantation. This finding strongly suggests that thiazolidinedione treatment attenuates diffuse in-stent restenosis in diabetic patients. (author abst.) |
|
|
|
Related Articles;
|
|
|
